![](https://i.imgur.com/CLvY2jA.png")
16-11-2021, 09:04 PM
15 Nov, 2021 08:33 / Updated 1 day ago
A British company is moving towards phase 1 trials for its novel Covid-19 vaccine, which is applied as a skin patch and uses T-cells to fight back against the virus.
......
the vaccine’s sole purpose was to “generate a targeted T-cell response” rather than an antibody response.
While the antibody response, engendered by overcoming infection or the administration of one of the current cohorts of widely used vaccines, wanes over time, the Emergex skin patch could offer longer-lasting immunity – possibly for decades, according to Cohen.
https://www.rt.com/uk/540281-covid19-vac...kin-patch/
A British company is moving towards phase 1 trials for its novel Covid-19 vaccine, which is applied as a skin patch and uses T-cells to fight back against the virus.
......
the vaccine’s sole purpose was to “generate a targeted T-cell response” rather than an antibody response.
While the antibody response, engendered by overcoming infection or the administration of one of the current cohorts of widely used vaccines, wanes over time, the Emergex skin patch could offer longer-lasting immunity – possibly for decades, according to Cohen.
https://www.rt.com/uk/540281-covid19-vac...kin-patch/
